We thank Dr Sorrentino for his critical and positive review of our recent article, “Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, or Corticosteroid-Free Remission in Patients With Active Luminal Crohn’s Disease” published in Gastroenterology 2018.1